Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: A hospital-based retrospective study

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 736-741

  Chang, Hong Jyun ^a   Hsu, Po Chang ^a   Yang, Chien Chang ^a   Siu, Leung Kei ^b   Kuo, An Jing ^c   Chia, Ju Hsin ^c   Wu, Tsu Lan ^c   Huang, Ching Tai ^a   Lee, Ming Hsun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Mortality; MRSA; Susceptibility

Indexed keywords

TEICOPLANIN; TEICOPLANIN ETEST; UNCLASSIFIED DRUG; VANCOMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BLOOD CULTURE; BONE AND JOINT INFECTIONS; CARDIOVASCULAR INFECTION; CATHETER INFECTION; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LENGTH OF STAY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; SOLID TUMOR; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; FEMALE; HOSPITALS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863075996     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr531     Document Type: Article

References (28)

1. Cosgrove SE, Qi Y, Kaye KS et al. The impact of methicillin resistance in Staphylococcus aureus bacteraemia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-74.
2. Fowler VG, Reed SD, Friedman JY et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteraemia. Infect Control Hosp Epidemiol 2005; 26: 175-83.
3. Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115: 739-41.
4. Richards MJ, Edwards JR, Culver DH et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 887-92.
5. Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcareassociated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
6. Rosenthal VD, Maki DG, Mehta A et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36: 627-37.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
8. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteraemia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
9. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60: 788-94.
10. Mason EO, Lamberth LB, Hammerman WA et al. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 2009; 47: 1628-30.
11. Wang GQ, Hindler JF, Ward KW et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883-6.
12. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
13. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 2004; 42: 2398-402.
14. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42 Suppl 1: S40-50.
15. Lin SH, Lai CC, Tan CK et al. Comparative efficacy of vancomycin and teicoplanin in the treatment of hospitalised elderly patients with persistent meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Int J Antimicrob Agents 2011; 37: 179-81.
16. Wilson AP, Cepeda JA, Hayman S et al. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients. J Antimicrob Chemother 2006; 58: 470-3.
17. Pasticci MB, Moretti A, Stagni G et al. Bactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: looking for a relationship between tolerance and outcome. Ann Clin Microbiol Antimicrob 2011; 10: 26.
18. Bannerman TL, Peacock SJ. Staphylococcus, Micrococcus, and other catalase-positive cocci. In: Murray PR, Baron EJ, Jorgensen JH et al., eds. Manual of Clinical Microbiology, 9th edn. Washington, DC: American Society of Microbiology, 2007; 390-411.
19. EUCAST. European Committee on Antimicrobial Susceptibility Testing (EUCAST): breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf (5 January 2011, date last accessed).
20. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53: 4069-79.
21. Charlesworth R, Warner M, Livermore DM et al. Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 186-9.
22. Wong-Beringer A, Hsu DI, Hidayat LK et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32: 378-85.
23. Bland CM, Porr WH, Davis KA et al. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etestw and an automated testing method. South Med J 2010; 103: 1124-8.
24. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
25. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 2008; 46: 193-200.
26. Walraven CJ, North MS, Marr-Lyon L et al. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66: 2386-92.
27. Wang JL, Wang JT, Sheng WH et al. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in Taiwan: mortality analyses and the impact of vancomycin, MIC=2 mg/L, by the broth microdilution method. BMC Infect Dis 2010; 10: 159-65.
28. Khatib R, Jose J, Musta A et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66: 1594-9.